COO appointment puts Enovix operations in the spotlight
Enovix (ENVX) drew fresh attention after appointing Dr. Michael Vyvoda as Chief Operating Officer, a move that highlights how closely investors are watching the company’s push toward high volume battery manufacturing.
The announcement comes shortly after Enovix stock fell from about $7 to near $5, with the latest update on its battery technology drawing negative sentiment and leaving the share price under pressure in recent weeks.
See our latest analysis for Enovix.
For context, Enovix’s recent selling pressure has been pronounced, with the 30 day share price return down about 30% and the 1 year total shareholder return falling roughly 63%. This signals fading momentum, despite the COO appointment aiming to improve execution and operations.
If the recent volatility around Enovix has you reassessing your watchlist, this could be a good moment to look at other growth stories in battery and power technology supply chains using the 35 power grid technology and infrastructure stocks
After Enovix stock slid hard despite the COO hire and a price target that sits well above the current share price, the next issue is straightforward: is most of the upside still ahead, or has it already been priced in?
Most Popular Narrative: 60.9% Undervalued
Analysts following Enovix see a fair value of $13.10 per share versus the last close at $5.13, framing the recent sell off against a much higher narrative benchmark.
Completion of the site acceptance testing for the high volume manufacturing line in Malaysia is set to boost production capacity and support significant revenue growth with a focus on readiness for smartphone mass production in the fourth quarter of 2025. Successful shipment of early engineering smartphone battery samples and positive safety test results indicate future revenue increase potential, pending successful customer qualification for anticipated commercial smartphone launches in 2025.
Curious what kind of revenue surge, margin shift, and future profit multiple are baked into that $13.10 fair value for Enovix, and how long the model assumes it takes to get there.
Result: Fair Value of $13.10 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Enovix still faces meaningful risks, including potential delays in smartphone customer qualification and the cash strain that could come from high capital manufacturing investments.
Find out about the key risks to this Enovix narrative.
Another View on Enovix Valuation
The analyst fair value of $13.10 paints Enovix as undervalued, but the market is also clearly looking at the current P/S ratio of 31.8x, which is far higher than the US Electrical industry at 2.6x, peer average at 8.9x, and a fair ratio of 5.4x. This raises questions about how much future success is already embedded in the price.
For a closer look at what this gap between today’s rich sales multiple and the lower fair ratio might mean for upside and downside risk, you can review the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
On balance, do you feel the Enovix story leans more toward opportunity or risk right now, and are you ready to move past headlines and quickly review the details yourself, including the 1 key reward and 1 important warning sign
Looking for more investment ideas beyond Enovix?
If Enovix has sharpened your focus on opportunities and risks, do not stop there. Broaden your scope now so you are not relying on a single story.
- Pinpoint potential value candidates by scanning a curated set of 44 high quality undervalued stocks that may merit a closer look before the crowd pays attention.
- Strengthen your income watchlist by reviewing 9 dividend fortresses that combine higher yields with a focus on durability.
- Prioritize resilience by filtering for 72 resilient stocks with low risk scores that may help balance out more volatile positions in your portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com